Nxera Pharma Co Ltd (SOLTF)
9.55
+0.25
(+2.65%)
USD |
OTCM |
May 03, 16:00
Nxera Pharma Research and Development Expense (Quarterly): 20.74M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 20.74M |
| September 30, 2023 | 20.59M |
| June 30, 2023 | 15.17M |
| March 31, 2023 | 14.82M |
| December 31, 2022 | 12.99M |
| September 30, 2022 | 13.93M |
| June 30, 2022 | 14.62M |
| March 31, 2022 | 15.53M |
| December 31, 2021 | 14.07M |
| September 30, 2021 | 15.75M |
| June 30, 2021 | 12.71M |
| March 31, 2021 | 11.40M |
| December 31, 2020 | 10.50M |
| September 30, 2020 | 9.479M |
| June 30, 2020 | 9.497M |
| March 31, 2020 | 6.134M |
| December 31, 2019 | 10.48M |
| September 30, 2019 | 10.39M |
| June 30, 2019 | 9.217M |
| March 31, 2019 | 9.299M |
| December 31, 2018 | 10.69M |
| September 30, 2018 | 20.85M |
| Date | Value |
|---|---|
| June 30, 2018 | 17.01M |
| March 31, 2018 | 13.64M |
| December 31, 2017 | 10.94M |
| September 30, 2017 | 10.10M |
| June 30, 2017 | 9.900M |
| March 31, 2017 | 7.827M |
| December 31, 2016 | 6.149M |
| September 30, 2016 | 7.093M |
| June 30, 2016 | 8.611M |
| March 31, 2016 | 10.23M |
| December 31, 2015 | 6.923M |
| September 30, 2015 | 8.348M |
| June 30, 2015 | 7.213M |
| March 31, 2015 | 2.812M |
| December 31, 2014 | 0.7083M |
| September 30, 2014 | 0.6735M |
| June 30, 2014 | 0.6852M |
| March 31, 2014 | 1.045M |
| December 31, 2013 | 0.795M |
| September 30, 2013 | 0.5056M |
| June 30, 2013 | 0.6857M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.134M
Minimum
Mar 2020
20.74M
Maximum
Dec 2023
13.05M
Average
12.99M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 1.269B |
| PeptiDream Inc | 6.067M |
| Stemcell Holdings Inc | -- |
| Healios KK | 5.235M |
| AnGes Inc | 9.032M |